What is B. Riley’s Estimate for DNLI Q1 Earnings?

Denali Therapeutics Inc. (NASDAQ:DNLI) – B. Riley issued their Q1 2025 earnings per share estimates for shares of Denali Therapeutics in a note issued to investors on Friday, November 8th. B. Riley analyst M. Mamtani anticipates that the company will post earnings of ($0.77) per share for the quarter. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.53) per share. B. Riley also issued estimates for Denali Therapeutics’ Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.67) EPS, FY2025 earnings at ($2.71) EPS, FY2026 earnings at ($2.26) EPS and FY2027 earnings at ($1.20) EPS.

DNLI has been the topic of a number of other reports. HC Wainwright restated a “buy” rating and issued a $90.00 price objective on shares of Denali Therapeutics in a research note on Thursday. Bank of America lifted their target price on Denali Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Cantor Fitzgerald lowered Denali Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 7th. Citigroup lifted their target price on Denali Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Finally, Wedbush reduced their target price on Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $38.90.

Denali Therapeutics Stock Performance

Shares of Denali Therapeutics stock opened at $31.35 on Monday. Denali Therapeutics has a 52-week low of $14.56 and a 52-week high of $32.13. The stock’s 50-day simple moving average is $27.81 and its 200 day simple moving average is $23.62. The stock has a market capitalization of $4.51 billion, a P/E ratio of -11.36 and a beta of 1.40.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same quarter last year, the company posted ($0.72) earnings per share.

Insider Transactions at Denali Therapeutics

In other news, CEO Ryan J. Watts sold 40,000 shares of the business’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the completion of the transaction, the chief executive officer now owns 235,807 shares of the company’s stock, valued at approximately $6,529,495.83. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Denali Therapeutics news, Director Steve E. Krognes sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $29.03, for a total value of $870,900.00. Following the completion of the sale, the director now owns 29,096 shares in the company, valued at approximately $844,656.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Ryan J. Watts sold 40,000 shares of the business’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $27.69, for a total value of $1,107,600.00. Following the completion of the sale, the chief executive officer now owns 235,807 shares of the company’s stock, valued at $6,529,495.83. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.90% of the stock is owned by insiders.

Institutional Trading of Denali Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of DNLI. MONECO Advisors LLC raised its holdings in shares of Denali Therapeutics by 4.6% during the third quarter. MONECO Advisors LLC now owns 9,100 shares of the company’s stock valued at $265,000 after acquiring an additional 400 shares in the last quarter. Assetmark Inc. raised its holdings in shares of Denali Therapeutics by 18.0% during the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock valued at $111,000 after acquiring an additional 580 shares in the last quarter. CWM LLC raised its holdings in shares of Denali Therapeutics by 43.6% during the third quarter. CWM LLC now owns 2,153 shares of the company’s stock valued at $63,000 after acquiring an additional 654 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Denali Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock valued at $152,000 after acquiring an additional 920 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Denali Therapeutics by 5.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,403 shares of the company’s stock valued at $613,000 after acquiring an additional 1,372 shares in the last quarter. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.